Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice

Giovanni Caocci; Olga Mulas; Elisabetta Abruzzese; Alessandra Iurlo; Mario Annunziata; Ester Maria Orlandi; Sara Galimberti; Gianni Binotto; Nicola Sgherza; Luigia Luciano; Bruno Martino; Antonella Russo Rossi; Massimiliano Bonifacio; Claudio Fozza; Malgorzata Monika Trawinska; Daniele Cattaneo; Chiara Elena; Claudia Baratè; Fiorenza De Gregorio; Matteo Molica; Giorgio La Nasa; Robin Foà; Massimo Breccia

doi:10.1007/s00277-019-03705-y

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice

Giovanni Caocci, Olga Mulas, Elisabetta Abruzzese, Alessandra Iurlo, Mario Annunziata, Ester Maria Orlandi, Sara Galimberti, Gianni Binotto, Nicola Sgherza, Luigia Luciano, Bruno Martino, Antonella Russo Rossi, Massimiliano Bonifacio, Claudio Fozza, Malgorzata Monika Trawinska, Daniele Cattaneo, Chiara Elena, Claudia Baratè, Fiorenza De Gregorio, Matteo MolicaGiorgio La Nasa, Robin Foà, Massimo Breccia

Research output: Contribution to journal › Article

Abstract

There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high–very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.

Original language	English
Pages (from-to)	1885-1890
Journal	Annals of Hematology
Volume	98
Issue number	8
DOIs	https://doi.org/10.1007/s00277-019-03705-y
Publication status	Published - Jan 1 2019

Keywords

Acetylsalicylic acid
Bosutinib
Cardiovascular risk
Chronic myeloid leukemia

ASJC Scopus subject areas

Hematology

Access to Document

10.1007/s00277-019-03705-y

Fingerprint Dive into the research topics of 'Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice'. Together they form a unique fingerprint.

Cite this

Caocci, G., Mulas, O., Abruzzese, E., Iurlo, A., Annunziata, M., Orlandi, E. M., Galimberti, S., Binotto, G., Sgherza, N., Luciano, L., Martino, B., Russo Rossi, A., Bonifacio, M., Fozza, C., Trawinska, M. M., Cattaneo, D., Elena, C., Baratè, C., De Gregorio, F., ... Breccia, M. (2019). Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. Annals of Hematology, 98(8), 1885-1890. https://doi.org/10.1007/s00277-019-03705-y

Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. / Caocci, Giovanni; Mulas, Olga; Abruzzese, Elisabetta; Iurlo, Alessandra; Annunziata, Mario; Orlandi, Ester Maria; Galimberti, Sara; Binotto, Gianni; Sgherza, Nicola; Luciano, Luigia; Martino, Bruno; Russo Rossi, Antonella; Bonifacio, Massimiliano; Fozza, Claudio; Trawinska, Malgorzata Monika; Cattaneo, Daniele; Elena, Chiara; Baratè, Claudia; De Gregorio, Fiorenza; Molica, Matteo; La Nasa, Giorgio; Foà, Robin; Breccia, Massimo.

In: Annals of Hematology, Vol. 98, No. 8, 01.01.2019, p. 1885-1890.

Research output: Contribution to journal › Article

Caocci, G, Mulas, O, Abruzzese, E, Iurlo, A, Annunziata, M, Orlandi, EM, Galimberti, S, Binotto, G, Sgherza, N, Luciano, L, Martino, B, Russo Rossi, A, Bonifacio, M, Fozza, C, Trawinska, MM, Cattaneo, D, Elena, C, Baratè, C, De Gregorio, F, Molica, M, La Nasa, G, Foà, R & Breccia, M 2019, 'Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice', Annals of Hematology, vol. 98, no. 8, pp. 1885-1890. https://doi.org/10.1007/s00277-019-03705-y

Caocci, Giovanni ; Mulas, Olga ; Abruzzese, Elisabetta ; Iurlo, Alessandra ; Annunziata, Mario ; Orlandi, Ester Maria ; Galimberti, Sara ; Binotto, Gianni ; Sgherza, Nicola ; Luciano, Luigia ; Martino, Bruno ; Russo Rossi, Antonella ; Bonifacio, Massimiliano ; Fozza, Claudio ; Trawinska, Malgorzata Monika ; Cattaneo, Daniele ; Elena, Chiara ; Baratè, Claudia ; De Gregorio, Fiorenza ; Molica, Matteo ; La Nasa, Giorgio ; Foà, Robin ; Breccia, Massimo. / Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice. In: Annals of Hematology. 2019 ; Vol. 98, No. 8. pp. 1885-1890.

@article{d3d1b53b20604723bb8edf81f5a860b1,

title = "Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice",

abstract = "There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high–very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.",

keywords = "Acetylsalicylic acid, Bosutinib, Cardiovascular risk, Chronic myeloid leukemia",

author = "Giovanni Caocci and Olga Mulas and Elisabetta Abruzzese and Alessandra Iurlo and Mario Annunziata and Orlandi, {Ester Maria} and Sara Galimberti and Gianni Binotto and Nicola Sgherza and Luigia Luciano and Bruno Martino and {Russo Rossi}, Antonella and Massimiliano Bonifacio and Claudio Fozza and Trawinska, {Malgorzata Monika} and Daniele Cattaneo and Chiara Elena and Claudia Barat{\`e} and {De Gregorio}, Fiorenza and Matteo Molica and {La Nasa}, Giorgio and Robin Fo{\`a} and Massimo Breccia",

year = "2019",

month = jan,

day = "1",

doi = "10.1007/s00277-019-03705-y",

language = "English",

volume = "98",

pages = "1885--1890",

journal = "Revue d'h{\'e}matologie",

issn = "0939-5555",

publisher = "Springer Verlag",

number = "8",

}

TY - JOUR

T1 - Incidence and evaluation of predisposition to cardiovascular toxicity in chronic myeloid leukemia patients treated with bosutinib in the real-life practice

AU - Caocci, Giovanni

AU - Mulas, Olga

AU - Abruzzese, Elisabetta

AU - Iurlo, Alessandra

AU - Annunziata, Mario

AU - Orlandi, Ester Maria

AU - Galimberti, Sara

AU - Binotto, Gianni

AU - Sgherza, Nicola

AU - Luciano, Luigia

AU - Martino, Bruno

AU - Russo Rossi, Antonella

AU - Bonifacio, Massimiliano

AU - Fozza, Claudio

AU - Trawinska, Malgorzata Monika

AU - Cattaneo, Daniele

AU - Elena, Chiara

AU - Baratè, Claudia

AU - De Gregorio, Fiorenza

AU - Molica, Matteo

AU - La Nasa, Giorgio

AU - Foà, Robin

AU - Breccia, Massimo

PY - 2019/1/1

Y1 - 2019/1/1

N2 - There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high–very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.

AB - There is little information about cardiovascular adverse event (CV-AE) incidence in chronic myeloid leukemia (CML) patients treated with bosutinib in the real-life practice. We identified 54 consecutive CML patients treated with bosutinib, stratified according to the Systematic Coronary Risk Evaluation (SCORE) assessment, based on sex, age, smoking habits, systolic blood pressure, and total cholesterol levels. The 40-month cumulative incidence of CV-AEs was 25.2 ± 8.1%. Patients with the SCORE of high–very high showed a significantly higher incidence of CV-AEs (55 ± 12.9% vs 9 ± 9.5%; p = 0.002). Overall, 9 CV-AEs were reported, with 2 deaths attributed to CV-AE. In conclusion, the SCORE assessment before starting treatment is helpful in identifying CV-AE high-risk patients during bosutinib treatment.

KW - Acetylsalicylic acid

KW - Bosutinib

KW - Cardiovascular risk

KW - Chronic myeloid leukemia

UR - http://www.scopus.com/inward/record.url?scp=85065256448&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065256448&partnerID=8YFLogxK

U2 - 10.1007/s00277-019-03705-y

DO - 10.1007/s00277-019-03705-y

M3 - Article

AN - SCOPUS:85065256448

VL - 98

SP - 1885

EP - 1890

JO - Revue d'hématologie

JF - Revue d'hématologie

SN - 0939-5555

IS - 8

ER -